北京卡威生物医药科技

Beijing Kawei Biopharmaceutical Technology is a Chinese pharmaceutical company focused on the development, production, and commercialization of high-end generic and innovative small molecule therapeutics. The company rose to prominence as one of the first domestic manufacturers in China to receive approval for Adefovir Dipivoxil, a critical antiviral for chronic hepatitis B. Its core expertise lies in anti-infective agents and oncology, with a portfolio that includes several widely used treatments for viral hepatitis and solid tumors. Operating out of Beijing, the firm maintains integrated R&D and manufacturing capabilities that adhere to national GMP standards. Beijing Kawei continues to expand its pipeline by targeting high-prevalence diseases within the Chinese market.